BIOGEN INC. Goodwill, Acquired During Period
BIOGEN INC. (BIIB) reported Goodwill, Acquired During Period of $9.00 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2024-08-01
- BIOGEN INC. goodwill, acquired during period for the quarter ending 2024-06-30 was $0.00.
- BIOGEN INC. goodwill, acquired during period for the quarter ending 2024-03-31 was $9.00M.
- BIOGEN INC. goodwill, acquired during period for the quarter ending 2023-12-31 was -$592.80M.
- BIOGEN INC. goodwill, acquired during period for the quarter ending 2018-12-31 was $269.40M, a 46.64% decline year-over-year.
- BIOGEN INC. goodwill, acquired during period for fiscal 2023 was $464.50M.
- BIOGEN INC. goodwill, acquired during period for fiscal 2022 was $0.00.
- BIOGEN INC. goodwill, acquired during period for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- BIOGEN INC. goodwill, acquired during period for fiscal 2019 was $117.50M, a 89.12% decline from fiscal 2018.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $9.00M 10-Q · filed 2024-08-01 | -$583.80M derived: sum of 3 quarters · filed 2024-08-01 | |
| 2024-03-31 | $9.00M 10-Q · filed 2024-04-24 | -$583.80M derived: sum of 2 quarters · filed 2024-04-24 | ||
| 2023-12-31 | -$592.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $464.50M 10-K · filed 2024-02-14 | ||
| 2023-09-30 | $1.06B 10-Q · filed 2023-11-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-02-03 | |||
| 2019-12-31 | $117.50M 10-K · filed 2021-02-03 | |||
| 2018-12-31 | $269.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $539.20M derived: sum of 2 quarters · filed 2020-02-06 | $809.60M derived: sum of 3 quarters · filed 2020-02-06 | $1.08B 10-K · filed 2020-02-06 |
| 2018-09-30 | $269.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $540.20M derived: sum of 2 quarters · filed 2018-10-23 | $810.70M 10-Q · filed 2018-10-23 | $1.32B derived: sum of 4 quarters · filed 2019-02-06 |
| 2018-06-30 | $270.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | $540.90M 10-Q · filed 2018-07-24 | $1.05B derived: sum of 3 quarters · filed 2019-02-06 | $1.30B derived: sum of 4 quarters · filed 2019-02-06 |
| 2018-03-31 | $270.50M 10-Q · filed 2018-04-24 | $775.40M derived: sum of 2 quarters · filed 2019-02-06 | $1.03B derived: sum of 3 quarters · filed 2019-02-06 | $1.28B derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-12-31 | $504.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $758.40M derived: sum of 2 quarters · filed 2019-02-06 | $1.01B derived: sum of 3 quarters · filed 2019-02-06 | $1.27B 10-K · filed 2019-02-06 |
| 2017-09-30 | $253.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $507.70M derived: sum of 2 quarters · filed 2017-10-24 | $762.40M 10-Q · filed 2017-10-24 | $1.02B derived: sum of 4 quarters · filed 2018-02-01 |
| 2017-06-30 | $254.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $508.90M 10-Q · filed 2017-07-25 | $764.50M derived: sum of 3 quarters · filed 2018-02-01 | $1.02B derived: sum of 4 quarters · filed 2018-02-01 |
| 2017-03-31 | $254.70M 10-Q · filed 2017-04-25 | $510.30M derived: sum of 2 quarters · filed 2018-02-01 | $766.60M derived: sum of 3 quarters · filed 2018-02-01 | $1.02B derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-12-31 | $255.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $511.90M derived: sum of 2 quarters · filed 2018-02-01 | $769.10M derived: sum of 3 quarters · filed 2018-02-01 | $1.03B 10-K · filed 2018-02-01 |
| 2016-09-30 | $256.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $513.50M derived: sum of 2 quarters · filed 2016-10-26 | $771.30M 10-Q · filed 2016-10-26 | $1.03B derived: sum of 4 quarters · filed 2017-02-02 |
| 2016-06-30 | $257.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $515.00M 10-Q · filed 2016-07-21 | $773.70M derived: sum of 3 quarters · filed 2017-02-02 | $1.03B derived: sum of 4 quarters · filed 2017-02-02 |
| 2016-03-31 | $257.80M 10-Q · filed 2016-04-21 | $516.50M derived: sum of 2 quarters · filed 2017-02-02 | $775.90M derived: sum of 3 quarters · filed 2017-02-02 | $1.07B derived: sum of 4 quarters · filed 2017-02-02 |
| 2015-12-31 | $258.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $518.10M derived: sum of 2 quarters · filed 2017-02-02 | $815.80M derived: sum of 3 quarters · filed 2017-02-02 | $908.10M 10-K · filed 2017-02-02 |
| 2015-09-30 | $259.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $557.10M derived: sum of 2 quarters · filed 2015-10-21 | $649.40M 10-Q · filed 2015-10-21 | $868.40M derived: sum of 4 quarters · filed 2016-02-03 |
| 2015-06-30 | $297.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $390.00M 10-Q · filed 2015-07-24 | $609.00M derived: sum of 3 quarters · filed 2016-02-03 | $785.40M derived: sum of 4 quarters · filed 2016-02-03 |
| 2015-03-31 | $92.30M 10-Q · filed 2015-04-24 | $311.30M derived: sum of 2 quarters · filed 2016-02-03 | $487.70M derived: sum of 3 quarters · filed 2016-02-03 | $619.60M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-12-31 | $219.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $395.40M derived: sum of 2 quarters · filed 2016-02-03 | $527.30M derived: sum of 3 quarters · filed 2016-02-03 | $527.30M 10-K · filed 2016-02-03 |
| 2014-09-30 | $176.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $308.30M derived: sum of 2 quarters · filed 2014-10-22 | $308.30M 10-Q · filed 2014-10-22 | $330.50M derived: sum of 4 quarters · filed 2015-02-04 |
| 2014-06-30 | $131.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $131.90M 10-Q · filed 2014-07-23 | $154.10M derived: sum of 3 quarters · filed 2015-02-04 | $154.10M derived: sum of 4 quarters · filed 2015-02-04 |
| 2014-03-31 | $0.00 10-Q · filed 2014-04-23 | $22.20M derived: sum of 2 quarters · filed 2015-02-04 | $22.20M derived: sum of 3 quarters · filed 2015-02-04 | $22.20M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-12-31 | $22.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $22.20M derived: sum of 2 quarters · filed 2015-02-04 | $22.20M derived: sum of 3 quarters · filed 2015-02-04 | $35.70M 10-K · filed 2015-02-04 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $13.50M 10-Q · filed 2013-10-28 | $10.10M derived: sum of 4 quarters · filed 2014-02-06 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $13.50M 10-Q · filed 2013-07-25 | $10.10M derived: sum of 3 quarters · filed 2014-02-06 | $10.10M derived: sum of 4 quarters · filed 2014-02-06 |
| 2013-03-31 | $13.50M 10-Q · filed 2013-04-25 | $10.10M derived: sum of 2 quarters · filed 2014-02-06 | $10.10M derived: sum of 3 quarters · filed 2014-02-06 | $14.70M derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | -$3.40M derived: sum of 2 quarters · filed 2014-02-06 | $1.20M derived: sum of 3 quarters · filed 2014-02-06 | $48.20M 10-K · filed 2014-02-06 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $4.60M derived: sum of 2 quarters · filed 2012-10-25 | $51.60M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $51.60M 10-Q · filed 2012-07-24 | ||
| 2012-03-31 | $47.00M 10-Q · filed 2012-05-01 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-02-05 | |||
| 2010-12-31 | $25.60M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |